## Maurizio Mascarin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3749557/publications.pdf

Version: 2024-02-01

430754 395590 102 1,422 18 33 citations g-index h-index papers 103 103 103 1961 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Treatment and outcome of intracranial ependymoma after first relapse in the 2nd AIEOP protocol. Neuro-Oncology, 2022, 24, 467-479.	0.6	5
2	Italian pediatric and adult oncology communities join forces for a national project dedicated to adolescents and young adults with cancer. Tumori, 2022, 108, 104-110.	0.6	8
3	Consensus on COVID-19 Vaccination in Pediatric Oncohematological Patients, on Behalf of Infectious Working Group of Italian Association of Pediatric Hematology Oncology. Journal of Clinical Medicine, 2022, 11, 1235.	1.0	4
4	Phase 2 study for nonmetastatic extremity highâ€grade osteosarcoma in pediatric and adolescent and young adult patients with a riskâ€adapted strategy based on ABCB1/Pâ€glycoprotein expression: An Italian Sarcoma Group trial (ISG/OSâ€2). Cancer, 2022, 128, 1958-1966.	2.0	12
5	Outcome of Children and Adolescents with Recurrent Classical Hodgkin Lymphoma: The Italian Experience. Cancers, 2022, 14, 1471.	1.7	3
6	A Textual Analysis for Understanding the Relations and the Identity Construction in Adolescent Oncology Patients: Retrospective Personal Views in Order to Educate Health Professionals. Behavioral Sciences (Basel, Switzerland), 2022, 12, 120.	1.0	1
7	Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group. Current Oncology Reports, 2022, 24, 843-860.	1.8	6
8	Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten. Tumori, 2022, 108, 402-406.	0.6	4
9	Favorable outcome of SARS-CoV-2 infection in pediatric hematology oncology patients during the second and third pandemic waves in Italy: a multicenter analysis from the Infectious Diseases Working Group of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP). Annals of Hematology. 2022. 101. 1843-1851.	0.8	8
10	Discussing communication issues and needs with adolescents with cancer. Tumori, 2021, 107, 360-363.	0.6	4
11	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. Neuro-Oncology, 2021, 23, 848-857.	0.6	24
12	MiR-26a-5p as a Reference to Normalize MicroRNA qRT-PCR Levels in Plasma Exosomes of Pediatric Hematological Malignancies. Cells, 2021, 10, 101.	1.8	21
13	Additional value of volumetric and texture analysis on FDG PET assessment in paediatric Hodgkin lymphoma: an Italian multicentric study protocol. BMJ Open, 2021, 11, e041252.	0.8	5
14	A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma. Hemato, 2021, 2, 264-280.	0.2	0
15	Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study. Tumori, 2021, , 030089162110172.	0.6	1
16	Proteomic Exploration of Plasma Exosomes and Other Small Extracellular Vesicles in Pediatric Hodgkin Lymphoma: A Potential Source of Biomarkers for Relapse Occurrence. Diagnostics, 2021, 11, 917.	1.3	13
17	Efficacy of dose intensification in induction therapy for localized Ewing sarcoma: Italian Sarcoma Group (ISG) and Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) ISG/AIEOP EW-1 study Journal of Clinical Oncology, 2021, 39, 11501-11501.	0.8	2
18	Whole Lung Irradiation after High-Dose Busulfan/Melphalan in Ewing Sarcoma with Lung Metastases: An Italian Sarcoma Group and Associazione Italiana Ematologia Oncologia Pediatrica Joint Study. Cancers, 2021, 13, 2789.	1.7	1

#	Article	IF	CITATIONS
19	Risks in Oncology and Radiation Therapy. , 2021, , 253-273.		1
20	Where Are Adolescents with Soft Tissue Sarcomas Treated? An Italian Nationwide Study on Referrals Based on Hospital Discharge Records. Journal of Adolescent and Young Adult Oncology, 2020, 9, 190-195.	0.7	7
21	HL-032: Nivolumab and Brentuximab Vedotin (BV)–Based, Response-Adapted Treatment in Children, Adolescents, and Young Adults (CAYA) With Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Primary Analysis of the Standard-Risk Cohort of the Phase 2 CheckMate 744 Study. Clinical Lymphoma. Myeloma and Leukemia. 2020. 20. S245-S246.	0.2	1
22	Can Desire and Wellbeing Be Promoted in Adolescents and Young Adults Affected by Cancer? PhotoTherapy as a Mirror That Increases Resilience. Frontiers in Psychology, 2020, 11, 966.	1.1	6
23	Evolving Services for Adolescents with Cancer in Italy: Access to Pediatric Oncology Centers and Dedicated Projects. Journal of Adolescent and Young Adult Oncology, 2020, 9, 196-201.	0.7	11
24	Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols. Cancers, 2020, 12, 1620.	1.7	10
25	Epstein-Barr virus BART microRNAs in EBV- associated Hodgkin lymphoma and gastric cancer. Infectious Agents and Cancer, 2020, 15, 42.	1.2	29
26	Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group. HemaSphere, 2020, 4, e329.	1.2	31
27	How to Reorganize Children's Access to Radiation Therapy in the Era of COVID-19, to Protect Them and Elderly Patients. Advances in Radiation Oncology, 2020, 5, 673-674.	0.6	2
28	Proteomic Profiles and Biological Processes of Relapsed vs. Non-Relapsed Pediatric Hodgkin Lymphoma. International Journal of Molecular Sciences, 2020, 21, 2185.	1.8	7
29	Maintenance therapy with oral cyclophosphamide plus celecoxib in patients with metastatic Ewing sarcoma: Results of the Italian Sarcoma Group/AIEOP EW-2 study Journal of Clinical Oncology, 2020, 38, 10517-10517.	0.8	2
30	Nivolumab and brentuximab vedotin (BV)-based, responseâ€adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis Journal of Clinical Oncology, 2020, 38, 8013-8013.	0.8	8
31	EPEN-03. LONG-TERM FOLLOW-UP OF AIEOP 2ND SERIES OF CHILDREN AND ADOLESCENT WITH PRIMARY INTRACRANIAL (ST:SUPRATENTORIAL; PF: POSTERIOR FOSSA) EPENDYMOMA AND METHYLATION GROUPS RE-ANALYSES. Neuro-Oncology, 2020, 22, iii308-iii308.	0.6	0
32	Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?. Child's Nervous System, 2019, 35, 2279-2287.	0.6	3
33	Value of the Rare Disease Registry of the Italian Region Friuli Venezia Giulia. Value in Health, 2019, 22, 1003-1011.	0.1	4
34	EP-1614 Incidence of second malignancies among pediatric patients treated with helical Tomotherapy. Radiotherapy and Oncology, 2019, 133, S870.	0.3	0
35	Dosimetric Analysis, Acute Toxicity and Long-Term Outcome of Craniospinal Irradiation Using Helical Tomotherapy in Children and Adults. International Journal of Radiation Oncology Biology Physics, 2019, 105, E624.	0.4	O
36	Response-Adapted Treatment with Nivolumab and Brentuximab Vedotin (BV) in Children, Adolescents and Young Adults (CAYA) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): CheckMate 744 Subgroup Analyses. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, S307.	0.2	1

#	Article	IF	CITATIONS
37	Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition. Journal of Clinical Medicine, 2019, 8, 1596.	1.0	15
38	The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 378-384.	0.6	3
39	Wilms tumor, medulloblastoma, and rhabdomyosarcoma in adult patients: lessons learned from the pediatric experience. Cancer and Metastasis Reviews, 2019, 38, 683-694.	2.7	22
40	FDG PET in response evaluation of bulky masses in paediatric Hodgkin's lymphoma (HL) patients enrolled in the Italian AIEOP-LH2004 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 97-106.	3.3	9
41	Multidisciplinary treatment approach for primary thyroid spindle cell sarcoma: A case report. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2019, 23, 46-49.	0.6	0
42	The concept of friendship in adolescents with cancer: Reflections and experiences. Tumori, 2019, 105, 5-11.	0.6	6
43	Classical pediatric Hodgkin lymphoma in very young patients: the Italian experience. Leukemia and Lymphoma, 2019, 60, 696-702.	0.6	3
44	Adjuvant chemotherapy to improve survival in average-risk adult medulloblastoma patients: Long-term results Journal of Clinical Oncology, 2019, 37, 2037-2037.	0.8	1
45	Long-term results of the AIEOP MH'96 childhood Hodgkin's lymphoma trial and focus on significance of response to chemotherapy and its implication in low risk patients to avoid radiotherapy. Leukemia and Lymphoma, 2018, 59, 2612-2621.	0.6	4
46	Sleep disorders in children with brain tumors: a pilot study based on a sleep disorder questionnaire. Child's Nervous System, 2018, 34, 1535-1540.	0.6	5
47	Italian Multicenter Study on Accuracy of 18 F-FDG PET/CT in Assessing Bone Marrow Involvement in Pediatric Hodgkin Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, e267-e273.	0.2	15
48	EPEN-03. PEDIATRIC INTRACRANIAL EPENDYMOMA: CORRELATION OF SYMPTOMS AND SIGNS AT RECURRENCE WITH OUTCOME IN THE SECOND PROSPECTIVE AIEOP PROTOCOL FOLLOW-UP. Neuro-Oncology, 2018, 20, i73-i74.	0.6	0
49	Proteomic Identification of Plasma Biomarkers in Children and Adolescents with Recurrent Hodgkin Lymphoma. Journal of Cancer, 2018, 9, 4650-4658.	1.2	14
50	EP-1246: Radiotherapy after autologous stem cell transplant in recurrent or refractory hodgkin's lymphoma. Radiotherapy and Oncology, 2018, 127, S689.	0.3	0
51	Pediatric intracranial ependymoma: correlating signs and symptoms at recurrence with outcome in the second prospective AIEOP protocol follow-up. Journal of Neuro-Oncology, 2018, 140, 457-465.	1.4	7
52	Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma. Blood, 2018, 132, 927-927.	0.6	13
53	Helical TomoTherapy in Pediatric-Adolescent Patients. Pediatric Oncology, 2018, , 381-406.	0.5	0
54	Winners' Cup: A National Football Tournament Brings Together Adolescent Patients with Cancer from all over Italy. Tumori, 2017, 103, e25-e29.	0.6	3

#	Article	IF	CITATIONS
55	HLA-G+3027 polymorphism is associated with tumor relapse in pediatric Hodgkin's lymphoma. Oncotarget, 2017, 8, 105957-105970.	0.8	5
56	Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma. Journal of Cancer, 2016, 7, 364-366.	1.2	18
57	EPN-02FINAL RESULTS OF THE 2ND AIEOP PROTOCOL FOR INTRACRANIAL EPENDYMOMA (EPD). Neuro-Oncology, 2016, 18, iii30.2-iii30.	0.6	0
58	EPN-15HYPOFRACTIONATED RADIOTHERAPY (RT) BOOST FOR CHILDREN WITH EPENDYMOMA AND A MEASURABLE RESIDUE AFTER SURGERY: FINAL RESULTS OF THE 2ND AIEOP PROTOCOL (ASSOCIAZIONE) TJ ETG	Qq <b>0.6</b> 0 rg	BTdOverlock
59	QOS-33PREVALENCE OF SLEEP DISORDERS IN CHILDREN WITH BRAIN TUMORS. Neuro-Oncology, 2016, 18, iii152.3-iii152.	0.6	0
60	Adolescents with Cancer in Italy: Improving Access to National Cooperative Pediatric Oncology Group (AIEOP) Centers. Pediatric Blood and Cancer, 2016, 63, 1116-1119.	0.8	14
61	Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. Neuro-Oncology, 2016, 18, 1451-1460.	0.6	108
62	OC-0541: Long-term results of the AIEOP MH-89 protocol for pediatric Hodgkin lymphoma. Radiotherapy and Oncology, 2016, 119, S256-S257.	0.3	1
63	EP-1415: Cranial irradiation and sleep disorders in children with brain tumour: a case-control study. Radiotherapy and Oncology, 2016, 119, S659.	0.3	0
64	EP-2084: Risk assessment of secondary cancer after craniospinal radiotherapy in childhood medulloblastoma. Radiotherapy and Oncology, 2016, 119, S982.	0.3	0
65	Abdomen/pelvis computed tomography in staging of pediatric Hodgkin Lymphoma: is it always necessary?. Cancer Medicine, 2016, 5, 2359-2367.	1.3	1
66	PV-0230: Risk assessment of solid secondary malignancies in childhood Hodgkin Lymphoma after radiotherapy. Radiotherapy and Oncology, 2016, 119, S104-S105.	0.3	0
67	Spiritual Support for Adolescent Cancer Patients: A Survey of Pediatric Oncology Centers in Italy and Spain. Tumori, 2016, 102, 376-380.	0.6	15
68	Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients?. Journal of Neuro-Oncology, 2016, 128, 235-240.	1.4	40
69	The prognostic value of biological markers in paediatric Hodgkin lymphoma. European Journal of Cancer, 2016, 52, 33-40.	1.3	13
70	Patient-Centered Cancer Care Programs in Italy: Benchmarking Global Patient Education Initiatives. Journal of Cancer Education, 2016, 31, 405-412.	0.6	10
71	New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Critical Reviews in Oncology/Hematology, 2015, 94, 348-359.	2.0	43
72	OC-0310: Hypofractionated radiotherapy (RT) boost for children with Ependymoma and a measurable residue after surgery. Radiotherapy and Oncology, 2015, 115, S155-S156.	0.3	3

#	Article	IF	Citations
<b>7</b> 3	Radiotherapy in Medulloblastoma. , 2015, , 363-380.		1
74	Pediatric advanced stage nasopharyngeal carcinoma - case report. Acta Medica Academica, 2015, 44, 186.	0.3	3
75	The German Hodgkin Study Group Stratification Scheme for Newly Diagnosed Hodgkin Lymphoma Is Useful for Predicting Outcome of Patients Receiving Radiation Therapy After Autologous Self Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma. International Journal of Radiation Oncology Biology Physics. 2014. 90. S671.	0.4	O
76	Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. Neuro-Oncology, 2014, 16, 748-753.	0.6	47
77	Cancer, Adolescence, and Their Peers: "They'll give you a Story― Journal of Cancer Education, 2014, 29, 434-440.	0.6	17
78	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). Tumori, 2014, 100, 612-619.	0.6	17
79	Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss). Tumori, 2014, 100, 612-9.	0.6	17
80	Dose to the skin in helical tomotherapy: Results of inÂvivo measurements with radiochromic films. Physica Medica, 2013, 29, 304-311.	0.4	26
81	Plasma Cell-Free DNA in Paediatric Lymphomas. Journal of Cancer, 2013, 4, 323-329.	1.2	48
82	The Youth Area Project at the Centro di Riferimento Oncologico in Aviano. Tumori, 2013, 99, e184-e185.	0.6	0
83	The youth area project at the Centro di Riferimento Oncologico in Aviano. Tumori, 2013, 99, e184-5.	0.6	0
84	Intensity-modulated radiotherapy (IMRT)/Tomotherapy following neoadjuvant chemotherapy in stage IIB–IVA/B undifferentiated nasopharyngeal carcinomas (UCNT): A mono-institutional experience. Oral Oncology, 2011, 47, 905-909.	0.8	6
85	Infant Ependymoma in a 10-Year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) Experience With Omitted or Deferred Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 80, 807-814.	0.4	31
86	Helical Tomotherapy in Children and Adolescents: Dosimetric Comparisons, Opportunities and Issues. Cancers, 2011, 3, 3972-3990.	1.7	10
87	Optimizing Craniospinal Radiotherapy Delivery in a Pediatric Patient Affected by Supratentorial PNET: A Case Report. Tumori, 2010, 96, 316-321.	0.6	5
88	A Case of Relapsed Medulloblastoma Treated with Intensity-Modulated Radiotherapy and Temozolomide. Tumori, 2010, 96, 327-331.	0.6	5
89	Starting an Adolescent and Young Adult Program: Some Success Stories and Some Obstacles to Overcome. Journal of Clinical Oncology, 2010, 28, 4850-4857.	0.8	199
90	Optimizing craniospinal radiotherapy delivery in a pediatric patient affected by supratentorial PNET: a case report. Tumori, 2010, 96, 316-21.	0.6	2

#	ARTICLE	IF	CITATIONS
91	Adolescents with cancer in Italy: Entry into the national cooperative paediatric oncology group AIEOP trials. European Journal of Cancer, 2009, 45, 328-334.	1.3	61
92	Salvage treatment for childhood ependymoma after surgery only: Pitfalls of omitting "at once― adjuvant treatment. International Journal of Radiation Oncology Biology Physics, 2006, 65, 1440-1445.	0.4	31
93	SECONDARY LEIOMYOSARCOMAS: A Report of 4 Cases. Pediatric Hematology and Oncology, 2005, 22, 181-187.	0.3	5
94	Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1336-1345.	0.4	93
95	Desmoplastic small round cell tumour in children and adolescents. , 2000, 34, 338-342.		40
96	The effect of granulocyte colony-stimulating factor on oral mucositis in head and neck cancer patients treated with hyperfractionated radiotherapy. Oral Oncology, 1999, 35, 203-208.	0.8	30
97	Combined radiotherapy and bleomycin in patients with inoperable head and neck cancer with unfavourable prognostic factors and severe symptoms. Oral Oncology, 1998, 34, 119-122.	0.8	25
98	Simultaneous radiochemotherapy in the treatment of inoperable, locally advanced head and neck cancers. A single-institution study. Cancer, 1995, 75, 1025-1029.	2.0	10
99	The Aged Patient with Lung Cancer. Drugs and Aging, 1994, 4, 34-46.	1.3	14
100	Anti-Rh(D) immunoglobulin for autoimmune neutropenia of infancy. Acta Paediatrica, International Journal of Paediatrics, 1993, 82, 142-144.	0.7	10
101	Avascular necrosis of bone in children undergoing allogeneic bone marrow transplantation. Cancer, 1991, 68, 655-659.	2.0	29
102	Brentuximab vedotin in the treatment of paediatric patients with relapsed or refractory Hodgkin's lymphoma: Results of a realâ€ife study. Pediatric Blood and Cancer, 0, , .	0.8	4